Media Clarification

RNS Number : 1241N
Abingdon Health PLC
27 January 2021
 

 

 

Media Clarification

 

York, U.K. 27 January 2021:  Abingdon Health (AIM: ABDX) notes an article by the Financial Times published this afternoon and provides the following clarification.

 

 

In its admission document published on 15 December 2020, the Company noted that it had received an order on 25 September 2020 from the Department for Health & Social Care ("DHSC") for 1 million tests out of an initial framework agreement for 10 million tests. It also stated that there were no guarantees of further orders from the DHSC and that the DHSC had the option to cancel its outstanding orders if a CE mark had not been granted for home use by 25 December 2020.

 

On 29 December 2020, Abingdon Health reiterated that the DHSC had the option to cancel outstanding orders if a CE mark had not been granted for home use by 25 December 2020 and confirmed that in any event the contract expired on 14th February 2021.

 

Subsequently, on 26 January, the Company announced that it had completed the delivery of its order of 1 million AbC-19 tests to the DHSC on 8 January 2021 and as noted previously, this contract will expire on 14 February 2021. The Company confirms that no further orders beyond the initial 1 million tests are expected to be placed under the DHSC contract. In-line with the Government's shift to a dynamic purchasing strategy, the Board expects that any future orders will be received via an application by the Company to future DHSC tender notices.  

 

 

Enquiries:

Abingdon Heath plc



Chris Yates

Chief Executive Officer

Via Consilium

Chris Hand

Non-Executive Chairman


Scott Page

Finance Director





N+1 Singer

Sole Broker and NOMAD

Tel: +44 (0) 20 7496 3000

Shaun Dobson, Pete Steel and Alex Bond (Corporate Finance)



Tom Salvesen (Corporate Broking)






Consilium

Financial PR

Tel: +44 (0) 7720 088 468

Matthew Neal


abingdonhealth@consilium-comms.com

Mary-Jane Elliott 



Lindsey Neville



 

 

 

About Abingdon Health

 

 

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England.

 

https://www.abingdonhealth.com/

 

 

AbC-19TM Rapid Test

The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUUGGUPGGRM
UK 100

Latest directors dealings